The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.
Alekya Devi AnalaInsiya Sajjad Hussain SaifudeenMaryam IbrahimMoksha NandaNida NaazStephen L AtkinPublished in: Journal of clinical medicine (2023)
Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age. The metabolic dysfunction associated with PCOS increases the probability of developing type 2 diabetes (T2D), endometrial cancer, and cardiovascular disease. Research has shown that the metabolic features of PCOS may be improved by weight loss following treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists. Tirzepatide is a dual GLP-GIP (gastric inhibitory polypeptide) receptor agonist that shares a very similar mechanism of action with GLP-1R agonists, and it is hypothesized that it may be a potential contender in the treatment of PCOS. The success of GLP-1R agonists is usually hindered by their adverse gastrointestinal effects, leading to reduced compliance. The mechanism of action of Tirzepatide partly addresses this issue, as its dual receptor affinity may reduce the intensity of gastrointestinal symptoms. Tirzepatide has been licensed for the treatment of type 2 diabetes and given the metabolic issues and obesity that accompanies PCOS, it may be of value in its management for those PCOS patients who are obese with metabolic syndrome, although it may not benefit those who are of normal weight. This study reviews the current therapies for the treatment of PCOS and evaluates the potential use of Tirzepatide to address the symptoms of PCOS, including reproductive dysfunction, obesity, and insulin resistance.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- metabolic syndrome
- type diabetes
- adipose tissue
- weight loss
- high fat diet
- skeletal muscle
- high fat diet induced
- cardiovascular disease
- endometrial cancer
- end stage renal disease
- bariatric surgery
- chronic kidney disease
- oxidative stress
- glycemic control
- pregnant women
- depressive symptoms
- coronary artery disease
- systematic review
- newly diagnosed
- emergency department
- body mass index
- peritoneal dialysis
- human health
- randomized controlled trial
- drug induced
- weight gain
- risk assessment
- pregnancy outcomes
- cardiovascular risk factors
- roux en y gastric bypass